BioSpace News Archive

Suzhou’s Innovent Plans Capital Raise Followed by $200M IPO

Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200M in late 2018.

January 16, 2018
·
1 min read
Drug Development

Constellation Pharmaceuticals Announces Initiation of Phase Ib/II Study of CPI-1205 in Combination with Checkpoint Inhibitors

Constellation Pharmaceuticals announced it has initiated a Phase 1b/2 clinical trial to evaluate CPI-1205, a small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2).

January 16, 2018
·
3 min read
Drug Development

Ophthotech Announces First Patient Enrolled in the Phase IIb Clinical Trial of Zimura, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease (STGD1).

January 16, 2018
·
6 min read
Drug Development

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

January 16, 2018
·
3 min read
Business

CompleWare and YPrime Announce Partnership Agreement

CompleWare and YPrime announce a partnership agreement to deliver enhanced service offerings involving clinical trials, eCOA technology and IRT.

January 16, 2018
·
2 min read
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies

Tenax announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

January 16, 2018
·
4 min read
Business

ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration

Under the terms of the agreement, ShangPharma Innovation will provide funding and preclinical research support to further ISMMS’s objectives of validating drug targets and establishing programs to discover new therapies.

January 16, 2018
·
4 min read
FDA

FDA Approves New Indication for Boehringer Ingelheim’s Gilotrif in EGFR Mutation-Positive NSCLC

The FDA granted Priority Review status to Gilotrif in evaluating this application.

January 16, 2018
·
9 min read
Biotech Bay

Another Large Pharma Implements Berkeley Lights’ Beacon OptoFluidic Platform for Accelerating Antibody Discovery

Berkeley Lights announced today that Novartis is implementing BLI’s Beacon platform to help accelerate their antibody discovery workflow.

January 16, 2018
·
2 min read
BioCapital

CEL-SCI Announces Adjustment to Warrant Exercise Price

CEL-SCI announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 per share of common stock for a three month period which will end on April 12, 2018.

January 16, 2018
·
3 min read